JAK2 and gastric cancer: In this study we demonstrate that WP1066 dose-dependently inhibits the JAK2/STAT3 signaling pathway in human gastric cancer (AGS) cells, with a consequent 60% reduction in cell proliferation, and a smaller increase in apoptosis.